Markets:

Overview

News

Currencies

International

Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.19 +0.12 (+0.50%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

October 21, 2025

Via Benzinga

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Emerges as a Strong Value Investing Opportunity ↗

August 13, 2025

PACIRA BIOSCIENCES (PCRX) is a strong value stock with undervalued P/E ratios, solid profitability, and stable finances, offering potential for long-term investors.

Via Chartmill

Pacira (PCRX) Q2 Revenue Rises 1.7% ↗

August 06, 2025

Via The Motley Fool

Pacira BioSciences Inc (NASDAQ:PCRX) Reports Mixed Q2 2025 Earnings with EPS Beat but Revenue Miss ↗

August 05, 2025

Pacira BioSciences (PCRX) reported mixed Q2 2025 results, with EPS beating estimates but revenue missing. Shares were flat post-release as investors weighed the performance. The company highlighted...

Via Chartmill

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Preview: Pacira BioSciences's Earnings ↗

May 07, 2025

Via Benzinga

A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts ↗

February 28, 2025

Via Benzinga

Insights Ahead: Pacira BioSciences's Quarterly Earnings ↗

August 04, 2025

Via Benzinga

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock Worth Considering ↗

July 08, 2025

PACIRA BIOSCIENCES (NASDAQ:PCRX) offers an undervalued opportunity with strong profitability, manageable debt, and steady growth, making it a candidate for value investors.

Via Chartmill

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Strong Fundamentals ↗

June 17, 2025

PACIRA BIOSCIENCES (PCRX) appears undervalued with strong profitability and steady growth, making it a potential candidate for value investors.

Via Chartmill

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) – An Undervalued Stock with Solid Fundamentals ↗

May 23, 2025

PACIRA BIOSCIENCES (PCRX) appears undervalued with strong profitability, steady growth, and reasonable financial health, making it a candidate for value investors.

Via Chartmill

Where Pacira BioSciences Stands With Analysts ↗

May 09, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Don't overlook PACIRA BIOSCIENCES INC (NASDAQ:PCRX)—a stock with solid growth prospects and a reasonable valuation. ↗

May 06, 2025

Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

PACIRA BIOSCIENCES INC (NASDAQ:PCRX): An Affordable Growth Stock Worth Watching ↗

May 01, 2025

PACIRA BIOSCIENCES INC (NASDAQ:PCRX): An Affordable Growth Stock Worth Watching

Via Chartmill

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. ↗

April 28, 2025

PACIRA BIOSCIENCES INC may be an undervalued stock option. NASDAQ:PCRX retains a strong financial foundation and an attractive price tag.

Via Chartmill

Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday ↗

April 21, 2025

Via Benzinga

PACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock which is not overvalued. ↗

April 15, 2025

Via Chartmill

Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars ↗

April 08, 2025

RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and...

Via Stocktwits

Topics Intellectual Property

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps ↗

April 08, 2025

Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no earlier than 2039.

Via Benzinga

Topics Intellectual Property

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday ↗

April 08, 2025

Via Benzinga

Forecasting The Future: 8 Analyst Projections For Pacira BioSciences ↗

April 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 08, 2025

Via Benzinga

Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice ↗

April 08, 2025

As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.

Via Stocktwits

Topics Intellectual Property Lawsuit

Wondering what's happening in today's after-hours session? ↗

April 07, 2025

After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.

Via Chartmill

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 07, 2025

Via Benzinga

PACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals. ↗

April 05, 2025

PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.

Via Chartmill

3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX ↗

March 05, 2025

The medical sector is usually of interest during economic uncertainty, especially when it leads to heightened stock market volatility.

Via Talk Markets

Topics Stocks / Equities

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

Headline News about Pacira BioSciences, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today